Tag: drug eluting stent market report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Drug Eluting Stent Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The drug eluting stent market size has experienced robust expansion in recent years. It is anticipated to increase from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical development can be ascribed to an escalating prevalence of coronary artery disease, an uptick in percutaneous coronary intervention procedures, a growing occurrence of lifestyle-related cardiovascular conditions, the broadening of cardiac catheterization labs, and enhanced clinical outcomes when compared to bare-metal stents.

The drug eluting stent market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $11.7 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period is attributable to factors such as an expanding aging population, a heightened demand for minimally invasive cardiac procedures, increasing awareness regarding advanced stent technologies, the proliferation of specialty cardiac clinics, and increased healthcare spending on cardiovascular care. Significant trends expected during this period involve the increasing adoption of biodegradable polymer stents, a growing inclination towards polymer-free drug-eluting stents, their expanded application in complex coronary interventions, a movement towards long-term restenosis prevention, and a heightened demand for enhanced drug release control.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=71881914&type=smp&name=Drug%20Eluting%20Stent%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Eluting Stent Market Demand Drivers Opening New Revenue Streams

The increasing prevalence of coronary heart disease (CHD) is anticipated to drive expansion in the drug-eluting stent market moving ahead. CHD refers to a condition characterized by the constriction or obstruction of coronary arteries from plaque accumulation, which can result in serious issues like heart attacks or angina. Factors contributing to the rise in coronary heart disease include inactive lifestyles, inadequate nutrition, an aging global demographic, and improved diagnostic awareness. Drug-eluting stents (DES) offer advantages in treating coronary heart disease by efficiently unblocking constricted arteries and delivering drugs to inhibit the re-narrowing, known as restenosis, of these vessels. As an illustration, data from August 2025, provided by the National Center for Biotechnology Information, a US governmental body, indicates that from 2025 to 2050, cardiovascular disease is forecasted to experience a substantial surge, with its prevalence climbing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%. This trajectory suggests approximately 35.6 million cardiovascular deaths by 2050, an increase from 20.5 million in 2025. This growing incidence of coronary heart disease is anticipated to fuel the expansion of the drug-eluting stent market.

Drug Eluting Stent Market Segment Performance And Emerging Opportunities

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Drug Eluting Stent Market Trends Powering Strategic Industry Growth

Leading companies within the drug eluting stent market are concentrating on developing innovative products, such as low-profile, high-flexibility stents, to enhance deliverability in complex coronary anatomies and improve patient outcomes. These specific stents are drug eluting stents engineered with a reduced crossing profile and increased flexibility, allowing for easier navigation through narrow, tortuous, or calcified coronary arteries, while maintaining effective drug delivery to prevent restenosis. For example, in May 2024, Abbott Laboratories, a U.S.-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design offering best-in-class deliverability, with significantly reduced crossing force when compared to competitors. It also incorporates a thinner balloon and an optimized MULTI LINK structure that enhances flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it provides a wide expansion range, permitting precise treatment even when vessel diameters vary markedly along the lesion, enabling interventional cardiologists to treat complex, calcified, or difficult-to-reach lesions with improved precision and safety.

Drug Eluting Stent Market Competitive Overview And Top Companies

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

View The Full Drug Eluting Stent Market Report:

https://thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Eluting Stent Market Leading Geography: Which Region Contributes The Most Revenue?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Drug Eluting Stent Market Progress Between 2026 And 2030?

The drug eluting stent market has demonstrated robust growth in recent years. It is expected to expand from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical development can be linked to factors such as the increasing prevalence of coronary artery disease, a rise in percutaneous coronary intervention procedures, the growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization labs, and enhanced clinical outcomes when compared to bare-metal stents.

The drug eluting stent market size is projected to experience substantial expansion over the upcoming years. It is predicted to reach $11.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. The expansion during the forecast timeframe can be attributed to an increasing aging population, a heightened demand for minimally invasive cardiac treatments, growing awareness of advanced stent technologies, the proliferation of specialty cardiac clinics, and elevated healthcare expenditure on cardiovascular care. Major trends anticipated in this period include a greater uptake of biodegradable polymer stents, a developing preference for polymer-free drug-eluting stents, their expanded application in complex coronary interventions, a movement towards long-term restenosis prevention, and a rising requirement for improved drug release control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Key Factors Are Shaping The Drug Eluting Stent Market Landscape?

The increasing prevalence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) refers to a condition characterized by the narrowing or obstruction of coronary arteries due to plaque accumulation, which can result in serious issues like heart attacks or angina. Factors contributing to the rise in coronary heart disease include inactive lifestyles, unhealthy eating habits, an aging demographic, and increased diagnostic awareness. Drug-eluting stents (DES) offer advantages in managing coronary heart disease by efficiently opening constricted or blocked coronary arteries and delivering drugs that inhibit the re-narrowing (restenosis) of the artery. An illustrative example, cited in August 2025 by the National Center for Biotechnology Information, a US-based governmental agency, indicates that cardiovascular disease is expected to see a substantial increase between 2025 and 2050. During this period, prevalence is forecast to climb by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%. This rise is predicted to result in approximately 35.6 million cardiovascular deaths in 2050, an increase from 20.5 million in 2025. Consequently, the growing burden of coronary heart disease is set to further boost the drug-eluting stench market.

What Are The Key Segment Divisions In The Drug Eluting Stent Market Segment Structure?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Market Trends Are Affecting The Drug Eluting Stent Market?

Leading firms in the drug eluting stent sector are prioritizing the creation of advanced products like low-profile, high-flexibility stents, aiming to boost deliverability within intricate coronary anatomies and elevate patient results. Such a stent is characterized by a minimized crossing profile and increased flexibility, enabling simpler navigation through constricted, winding, or calcified coronary arteries, all while ensuring consistent drug delivery to deter restenosis. An illustration of this is Abbott Laboratories, a global healthcare company from the U.S., introducing the XIENCE Sierra Everolimus Eluting Coronary Stent System to India in May 2024. The XIENCE Sierra boasts an innovative stent architecture that provides top-tier deliverability, notably lowering crossing force compared to competing products. Additionally, it incorporates a slimmer balloon and an improved MULTI LINK structure for greater flexibility, complemented by high longitudinal strength that guarantees scaffold stability and resilience against deformation. Furthermore, its broad expansion capacity facilitates precise treatment, even when vessel diameters vary considerably across the lesion, empowering interventional cardiologists to address intricate, calcified, or hard-to-access lesions with enhanced accuracy and safety.

Which Organizations Are Engaged In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Get The Full Drug Eluting Stent Market Report:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Which Region Is The Top Contributor To The Drug Eluting Stent Market By Share?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Eluting Stent Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Bioabsorbable Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Self Expanding Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Drug Eluting Stent Market At The End Of The 2026–2030 Forecast Period?

The drug eluting stent market has shown substantial growth in recent years. It is forecast to increase from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This market’s historical development can be attributed to the rising prevalence of coronary artery disease, the increase in percutaneous coronary intervention procedures, a growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization laboratories, and superior clinical outcomes compared to bare-metal stents.

The drug eluting stent market size is projected to experience substantial expansion over the coming years. This market is set to reach $11.7 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this anticipated growth during the forecast period encompass an expanding elderly demographic, a heightened need for less invasive cardiac procedures, increasing understanding of sophisticated stent innovations, the proliferation of specialized cardiac centers, and greater healthcare spending on heart-related conditions. Key developments anticipated in the forecast period include a rise in the uptake of biodegradable polymer stents, an increasing preference for polymer-free drug-eluting stents, wider application in intricate coronary interventions, a move towards preventing long-term restenosis, and a greater need for enhanced drug release management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Primary Drivers Are Shaping The Development Of The Drug Eluting Stent Market?

The increasing incidence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the coming years. Coronary heart disease (CHD) is characterized by the narrowing or obstruction of coronary arteries due to plaque accumulation, which can result in serious issues like heart attacks or angina. This condition is on the rise, primarily influenced by inactive lifestyles, unhealthy eating habits, an aging global demographic, and increased detection rates. Drug-eluting stents (DES) offer advantages in managing coronary heart disease by efficiently widening constricted or blocked coronary arteries and releasing drugs to inhibit the re-narrowing (restenosis) of the artery. As an illustration, the National Center for Biotechnology Information, a US government agency, indicated in August 2025 that cardiovascular disease is forecast to grow substantially between 2025 and 2050. This includes a projected 90.0% increase in prevalence, a 73.4% rise in crude mortality, and a 54.7% surge in crude DALYs, culminating in an estimated 35.6 million cardiovascular deaths by 2050, an increase from 20.5 million in 2025. This escalating burden of coronary heart disease is therefore expected to significantly boost the growth of the drug-eluting stent market.

What Segment Types Make Up The Drug Eluting Stent Market?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Which Market Trends Are Creating New Opportunities In The Drug Eluting Stent Market?

Leading firms in the drug eluting stent market are prioritizing the creation of advanced products, like stents with low profiles and high flexibility, aiming to boost their navigability in intricate coronary structures and better patient results. Specifically, a low-profile, high-flexibility stent is a drug eluting stent engineered with a smaller cross-sectional area and increased pliability, enabling smoother passage through constricted, winding, or hardened coronary arteries while ensuring consistent drug release to avert re-narrowing. An example of this is the launch of the XIENCE Sierra Everolimus Eluting Coronary Stent System in India by Abbott Laboratories, a U.S.-based global healthcare company, in May 2024. The XIENCE Sierra boasts an innovative stent architecture, providing superior deliverability with a substantially lower crossing force compared to its rivals. Furthermore, it incorporates a thinner balloon and a refined MULTI LINK structure for improved flexibility, along with robust longitudinal strength that guarantees scaffold integrity and resilience against distortion. Moreover, its broad expansion capabilities facilitate accurate treatment even when vessel diameters fluctuate significantly across a lesion, empowering interventional cardiologists to manage intricate, calcified, or hard-to-access lesions with enhanced accuracy and safety.

Who Are The Key Players Driving Competition In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Read the full drug eluting stent market report here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

How Does The Drug Eluting Stent Market Perform Across Major Global Regions?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Drug Eluting Stent Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Bioabsorbable Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Self Expanding Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Drug Eluting Stent Market expected to reach by 2030?

The drug eluting stent market size has experienced substantial growth in recent years. It is projected to expand from $8.26 billion in 2025 to reach $8.94 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical increase in the market can be attributed to factors such as the rising prevalence of coronary artery disease, an increase in percutaneous coronary intervention procedures, the growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization labs, and improved clinical outcomes when compared to bare-metal stents.

The drug eluting stent market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $11.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion over the forecast period is fueled by factors such as an expanding aging demographic, a heightened need for minimally invasive cardiac procedures, increasing knowledge of advanced stent innovations, the proliferation of specialized cardiac clinics, and greater spending on cardiovascular healthcare. Significant developments expected during this period involve the increasing embrace of biodegradable polymer stents, a growing inclination towards polymer-free drug-eluting stents, their expanded application in intricate coronary procedures, a move towards sustained restenosis prevention, and a heightened call for better drug release management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Drivers Are Driving Adoption Within The Drug Eluting Stent Market?

The increasing occurrence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) is characterized by the constriction or obstruction of coronary arteries due to plaque accumulation, which can result in serious health issues like heart attacks or angina. This rise in coronary heart disease is attributed to factors such as inactive living, inadequate nutritional habits, an expanding elderly demographic, and improved diagnostic understanding. Drug-eluting stents (DES) offer advantages in treating coronary heart disease by efficiently clearing narrowed or obstructed coronary arteries and administering drugs to inhibit restenosis, or the re-narrowing of the artery. For example, the National Center for Biotechnology Information, a US governmental entity, reported in August 2025 that cardiovascular disease is expected to grow substantially from 2025 to 2050, with its prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, ultimately causing an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. This escalating burden of coronary heart disease is consequently anticipated to stimulate growth within the drug-eluting stent market.

What Segments Are Included Within The Drug Eluting Stent Market?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Long-Term Trends Are Expected To Shape The Future Of The Drug Eluting Stent Market?

Leading companies within the drug eluting stent market are prioritizing the creation of innovative products, such as low-profile, high-flexibility stents, to enhance deliverability in intricate coronary anatomies and improve patient outcomes. A low-profile, high-flexibility stent refers to a drug eluting stent engineered with a reduced crossing profile and heightened flexibility, allowing it to navigate narrow, tortuous, or calcified coronary arteries with greater ease while maintaining effective drug delivery to prevent restenosis. As an illustration, in May 2024, Abbott Laboratories, a U.S.-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra showcases a novel stent design that provides best-in-class deliverability, with significantly reduced crossing force when compared to competitors. It also incorporates a thinner balloon and an optimized MULTI LINK structure to enhance flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Moreover, it offers a wide expansion range, permitting precise treatment even when vessel diameters vary markedly along the lesion—empowering interventional cardiologists to address complex, calcified, or challenging-to-reach lesions with improved precision and safety.

Who Are The Major Companies Operating In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Drug Eluting Stent Market?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drug Eluting Stent Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company

Vascular Stent Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Bioabsorbable Stents Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Self Expanding Stents Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the drug eluting stent market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Drug Eluting Stent Industry By 2029?

The drug eluting stent market size has experienced robust growth in recent years. This market is projected to expand from $7.63 billion in 2024 to $8.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. Historically, its expansion has been driven by factors such as the demand for enhanced treatment options, supporting clinical evidence, successful regulatory approvals, favorable healthcare economics, and established guidelines and recommendations.

The drug eluting stent market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $11.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.6%. This expected growth during the forecast period is largely driven by an aging population and increasing chronic disease burden, the broadening of indications, evolving healthcare reimbursement policies, continued global market expansion, and a growing emphasis on patient-centered care. Furthermore, significant trends anticipated in this period include personalized medicine, the adoption of minimally invasive techniques, advancements in emerging healthcare technologies, and the development of next-generation drug formulations.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Major Drivers Are Impacting The Drug Eluting Stent Market?

The growing prevalence of coronary heart disease is anticipated to drive expansion in the drug-eluting stent market in the foreseeable future. Coronary heart disease, or CHD, is characterized by the narrowing or blockage of coronary arteries from plaque accumulation, which can result in serious issues like heart attacks or angina. Factors contributing to the rise of coronary heart disease include inactive lifestyles, unhealthy eating habits, an aging demographic, and increased recognition of the condition. Drug-eluting stents, or DES, are advantageous for coronary heart disease because they efficiently open constricted or obstructed coronary arteries and deliver drugs that help prevent the arteries from re-narrowing, a process known as restenosis. As an example, in May 2024, data from the Centers for Disease Control and Prevention, a US-based governmental organization, showed that the prevalence of coronary heart disease among adults aged 18 and over was 4.6% in 2020, climbing to 4.9% by 2022. This increasing incidence of coronary heart disease is predicted to fuel the expansion of the drug-eluting stench market.

Which Segment Categories Are Driving Maximum Growth In The Drug Eluting Stent Market?

The drug eluting stentmarket covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Which Long-Term Trends Will Play A Crucial Role In The Drug Eluting Stent Market?

Entities operating within the drug-eluting stent market are channeling their efforts into developing advanced delivery systems, including the dual-layer balloon, with the aim of improving patient outcomes and propelling the field of interventional cardiology forward. Within a drug-eluting stent system, a dual-layer balloon significantly boosts the accuracy of drug delivery and stent deployment by enabling superior control and consistent drug application to the arterial wall. As an illustration, in August 2022, Medtronic Plc, a medical supplies provider based in Ireland, introduced Onyx Frontier, which represents the most recent iteration of drug-eluting coronary stent systems. This new system is engineered to refine delivery mechanisms, building upon the demonstrated acute performance and clinical evidence from its predecessor, the Resolute Onyx DES. The Onyx Frontier DES utilizes the identical top-tier stent platform as Resolute Onyx, featuring an extensive range of sizes suitable for treating patients with diameters spanning from 2.0mm to 5.0mm. Key design upgrades integrated into the Onyx Frontier DES include an innovative dual-layer balloon, a reduced crossing profile, and enhanced catheter flexibility. These enhancements collectively result in a 16% improvement in deliverability compared to the former Resolute Onyx DES generation, all while maintaining its radial strength.

Who Are The Dominant Players In The Drug Eluting Stent Market Today?

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Which Region Is At The Forefront Of Innovation In The Drug Eluting Stent Market?

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2025, By The Business Research Company

Drug Eluting Balloons Catheters Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Bioabsorbable Stents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Intracranial Stents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intracranial-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Drug Eluting Stent Industry In 2025?

The market for drug-eluting stents has experienced significant expansion recently, projected to advance from a value of $7.63 billion in 2024 to $8.26 billion the subsequent year, reflecting a compound annual growth rate (CAGR) of 8.3%. This upward trajectory during the past period is underpinned by several factors, including the demand for superior therapeutic alternatives, supportive clinical data, official endorsements, evolving healthcare financial considerations, and established clinical protocols and guidance.

Projected for robust expansion in the coming years, the market encompassing drug-eluting stents anticipates reaching a valuation of $11.07 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.6%; this upward trajectory during the forecast timeframe is fundamentally driven by demographic shifts toward an older populace and the increasing prevalence of long-term illnesses, alongside broader access facilitated by evolving healthcare coverage frameworks, the venturing into new territories globally, and a rising focus on patient-centric treatment modalities, while key developments shaping this period involve customized medical treatments, less invasive procedural approaches, advancements in pioneering health technologies, and the introduction of newer drug delivery systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

Which Major Market Drivers Are Shaping The Future Of The Drug Eluting Stent Market?

Increasing prevalence of coronary heart disease is anticipated to fuel the expansion of the drug-eluting stent sector in the future. This condition, characterized by the narrowing or obstruction of coronary arteries due to plaque accumulation, carries the risk of serious outcomes like myocardial infarction or angina pectoris. Factors such as increasingly inactive lifestyles, substandard dietary habits, the aging demographic, and greater public consciousness contribute to the heightened incidence of coronary heart disease. Drug-eluting stents prove beneficial in managing coronary heart disease by mechanically restoring flow in constricted or closed arteries and administering drugs designed to inhibit subsequent narrowing, known as restenosis. To illustrate the trend, data from the Centers for Disease Control and Prevention, a US government entity, showed that the proportion of adults aged 18 and above affected by coronary heart disease rose from 4.6% in 2020 to 4.9% in 2022, as reported in May 2024, suggesting the growing caseload will drive the drug-eluting stent market forward.

What Are The Major Segment Types Covered In The Drug Eluting Stent Market?

The drug eluting stentmarket covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Trends Are Redefining The Drug Eluting Stent Market Dynamics?

Within the arena of drug-eluting stents, firms are concentrating efforts on engineering novel deployment mechanisms, like the dual-layer balloon design, aspiring to elevate patient prognoses and propel progress in interventional cardiac procedures. This dual-layer balloon technology integrated into a drug-eluting stent apparatus sharpens the accuracy of both medicament dispersal and stent placement by affording superior manageability and consistent drug coating onto the vessel lining.Specifically, in August of 2022, Medtronic Plc, an Irish medical device manufacturer, introduced Onyx Frontier; this represents the most recent iteration of coronary drug-eluting stent systems engineered to build upon the immediate efficacy and clinical evidence established by its predecessor, the Resolute Onyx DES. Embodying the identical leading stent architecture found in the Resolute Onyx, the Onyx Frontier DES offers an extensive range of sizes, catering to patient vessels spanning from 2.0mm to 5.0mm in diameter. Significant structural augmentations characterize the Onyx Frontier DES, including an innovative dual-layer balloon, a lessened profile for navigating tight spaces, and enhanced catheter pliability, ultimately resulting in a 16 percent boost in the ease of delivery compared to the former Resolute Onyx DES generation, all maintained without compromising inherent radial force.

Which Key Players Are Driving Competition In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

What Regional Growth Trends Are Shaping The Drug Eluting Stent Market Outlook?

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Drug Eluting Stent Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2025, By The Business Research Company

Drug Eluting Balloons Catheters Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Bioabsorbable Stents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Intracranial Stents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intracranial-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Drug Eluting Stent Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent years, the market size for drug eluting stents has seen robust growth. It’s projected that this market will expand from $7.63 billion in 2024 to $8.26 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historical period can be ascribed to several factors such as the need for better treatment alternatives, clinical proof, healthcare economics, regulatory approval, and pertinent guidelines and recommendations.

The market for drug eluting stents is anticipated to witness robust expansion in the forthcoming years, and it is predicted to reach a valuation of $11.07 billion in 2029 with a CAGR of 7.6%. Factors driving this growth in the predicted period include the increasing aging population and burden of chronic diseases, broadening of indications, changes in healthcare reimbursement policies, expansion of the global market, and focus on patient-oriented care. Key trends during this projected period involve bespoke medicine, less intrusive procedures, emerging medical technologies, and innovative drug compounds.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Drug Eluting Stent Market?

The escalating issue of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD), a situation where the coronary arteries become obstructed or narrow due to plaque accumulation, can lead to severe health complications, such as chest pain or a heart attack. This disease is on the rise due to factors such as inactive lifestyles, inadequate diets, aging demographics, and increased general awareness. Drug-eluting stents (DES) offer significant benefits for coronary heart disease sufferers by effectively clearing blocked or narrow coronary arteries and discharging medication that curbs re-narrowing (restenosis) of the artery. For example, the Centers for Disease Control and Prevention, a government organization based in the US, reported in May 2024 that the prevalence of coronary heart disease in adults aged 18 and above went from 4.6% in 2020 to 4.9% in 2022. This escalating prevalence of coronary heart disease is anticipated to fuel the expansion of the drug-eluting stent market.

Which Primary Segments of the Drug Eluting Stent Market Are Driving Growth and Industry Transformations?

The drug eluting stentmarket covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Drug Eluting Stent Market?# Market?

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Drug Eluting Stent Market?

In the drug-eluting stent market, businesses are channeling their energies into the creation of unique delivery techniques, such as the innovative dual-layer balloon, aiming to improve patient results and contribute to the progress of interventional cardiology. The incorporation of a dual-layer balloon in a drug-eluting stent system contributes to more precise drug administration and stent positioning by augmenting control and ensuring uniform drug diffusion to the arterial wall. As an illustration, in August 2022, Medtronic Plc, an Irish firm specialized in medical supplies, introduced Onyx Frontier, the newest iteration of drug-eluting coronary stent systems. These are engineered to improve delivery systems, building on the acute performance and clinical findings from the previous Resolute Onyx DES version. The Onyx Frontier DES utilizes the same top-of-the-line stent platform as Resolute Onyx, offering a wide size matrix accommodating patients with diameters from 2.0mm to 5.0mm. The design of the Onyx Frontier DES includes exceptional advancements such as an innovative dual-layer balloon, decreased crossing profile, and enhanced catheter flexibility. These enhancements result in a 16% improvement in deliverability compared to the former Resolute Onyx DES series, while maintaining radial strength.

View the full report here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

What Parameters Are Used to Define the Drug Eluting Stent Market?

A drug-eluting stent (DES) is a medical device used in the treatment of coronary artery disease (CAD). It is a small, mesh-like tube typically made of metal that is inserted into narrowed or blocked coronary arteries during a procedure called percutaneous coronary intervention (PCI) or angioplasty.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15557

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Drug Eluting Stent Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market size of drug eluting stent has seen a robust increase. The market is projected to inflate from $7.63 billion in 2024 to $8.29 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the historic period include the demand for better treatment alternatives, clinical proof, regulatory consent, healthcare finance, and guidelines and suggestions.

What Is the Forecast for the Drug Eluting Stent Market Size Through 2029?

In the coming years, the market size for drug eluting stents is set for a significant expansion. It’s projected to escalate to $11.37 billion by 2029, indicating a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth during the forecast period include an older population dealing with chronic diseases, broader applications for the stents, healthcare reimbursement plans, and a worldwide expansion of the market alongside a focus on patient-centered care. The forecast period is also expected to witness key trends such as personalized treatment, less invasive procedures, developments in healthcare technology, and advanced drug formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What are the Key Market Players in Drug Eluting Stent Market and How They’re Evolving?

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

What Are the Primary Growth Drivers in the Drug Eluting Stent Market?

The drug-eluting stent market is projected to grow due to the increasing prevalence of coronary heart disease. This health condition, characterized by narrowing or blockage of the coronary arteries due to plaque accumulation, can potentially result in grave outcomes like heart attacks or chest pain. Sedentary lifestyles, poor dietary habits, aging demographics, and increased awareness are contributing to a rise in cases of coronary heart disease. Drug-eluting stents (DES), being effective in widening narrowed or blocked coronary arteries and dispensing medicine to avert re-narrowing (restenosis) of the artery, are found to be beneficial for this disease. As per the Centers for Disease Control and Prevention, a government agency based in the U.S., in May 2024, coronary heart disease’s prevalence in adults aged 18 and above had risen from 4.6% in 2020 to 4.9% in 2022. This accelerating rate of coronary heart disease is anticipated to boost the drug-eluting stent market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

What Are the Leading Segments in the Global Drug Eluting Stent Industry?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Are the Key Market Trends in the Drug Eluting Stent Industry?

Companies in the drug-eluting stent market are concentrating on the creation of groundbreaking delivery systems, like the dual-layer balloon, with the aim of enhancing patient results and elevating the practice of interventional cardiology. A dual-layer balloon within a drug-eluting stent system brings about increased accuracy in drug distribution and stent deployment by ensuring superior management and balanced drug exposure to the arterial wall. For instance, Medtronic Plc, a medical equipment supplier based in Ireland, introduced Onyx Frontier in August 2022. This is a new generation of drug-eluting coronary stent systems that are designed to improve delivery systems founded on the acute performance and clinical data of the earlier generation, Resolute Onyx DES. The new system, Onyx Frontier DES, maintains the same high-quality stent platform as Resolute Onyx and caters to a wide range of patients with diameters between 2.0mm to 5.0mm. The Onyx Frontier DES features significant design improvements such as a revolutionary dual-layer balloon, lessened crossing profile, and enhanced catheter flexibility. These advances lead to a 16% surge in deliverability compared to the former generation of Resolute Onyx DES, while still maintaining radial strength.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

What Is the Regional Outlook for the Drug Eluting Stent Market?

North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15557

This Report Delivers Insight On:

1. How big is the drug eluting stent market, and how is it changing globally?

2. Who are the major companies in the drug eluting stent market, and how are they performing?

3. What are the key opportunities and risks in the drug eluting stent market right now?

4. Which products or customer segments are growing the most in the drug eluting stent market?

5. What factors are helping or slowing down the growth of the drug eluting stent market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the drug eluting stent industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Drug Eluting Stent Market Size Shifted, And What Is the Outlook Through 2034?

The size of the market for drug eluting stents has seen robust growth in the recent past. There is an expected escalation from $7.63 billion in 2024 to $8.29 billion in 2025, with a compound annual growth rate (CAGR) of 8.6%. Factors such as the demand for better treatment alternatives, clinical proof, regulatory sanction, health care economics, as well as guidelines and commendations, have contributed to the growth in the previous phase.

The market size of drug-eluting stent is predicted to experience significant growth in the forthcoming years, expanding to a substantial $11.37 billion in 2029 with a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this projected growth in the forecast period include an increase in elderly population and chronic diseases, widening of indications, healthcare reimbursement policies, worldwide market expansion, and a focus on patient-centric care. The forecast period will also see key trends such as personalized medicine, minimally invasive procedures, emerging healthcare technologies, and advanced drug formulations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What are the Fundamental Drivers and Innovations Shaping the Drug Eluting Stent Market?

The drug-eluting stent market’s growth is likely to be fueled by the escalating prevalence of coronary heart disease. This disease causes the coronary arteries to become narrowed or blocked due to the accumulation of plaque, potentially resulting in serious consequences such as heart attacks or chest pain. The rise in coronary heart disease is accredited to inactive lifestyles, unhealthy diets, aging demographics, and increased awareness. Drug-eluting stents (DES) can significantly alleviate coronary heart disease by efficiently unblocking or widening constricted coronary arteries and discharging drugs that hinder the artery from becoming narrow again (restenosis). The Centers for Disease Control and Prevention, an American governmental entity, reported in May 2024 that the prevalence of coronary heart disease in adults aged 18 and older in 2020 stood at 4.6%, surging to 4.9% in 2022. This surge in coronary heart disease is projected to stimulate the growth of the drug-eluting stent market.

How Is the Drug Eluting Stent Market Segmented?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Which Regions Are Driving the Next Phase of the Drug Eluting Stent Market Growth?

North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Drug Eluting Stent Industry?

Firms working in the drug-eluting stent market are concentrating on developing innovative delivery methods like the dual-layer balloon in order to enhance patient results and make strides in the area of interventional cardiology. The use of a dual-layer balloon in drug-eluting stent systems offers enhanced accuracy in drug delivery and stent deployment by granting better control and consistent drug application to the arterial wall. For example, in August 2022, Medtronic Plc, a healthcare solutions supplier based in Ireland, introduced Onyx Frontier, the most recent version of drug-eluting coronary stent systems designed to improve upon delivery systems and build on the acute performance and clinical data of the previous generation, Resolute Onyx DES. The Onyx Frontier DES utilizes the same leading-edge stent platform as the Resolute Onyx, catering to a wide size matrix to accommodate patients with diameters ranging from 2.0mm to 5.0mm. The Onyx Frontier DES includes noteworthy design enhancements, including an innovative dual-layer balloon, a minimized crossing profile, and enhanced catheter flexibility. These updates result in a 16% deliverability increase compared to the previous Resolute Onyx DES generation, without compromising radial strength.

View the full report here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

How Is the Drug Eluting Stent Market Defined and What Are Its Core Parameters?

A drug-eluting stent (DES) is a medical device used in the treatment of coronary artery disease (CAD). It is a small, mesh-like tube typically made of metal that is inserted into narrowed or blocked coronary arteries during a procedure called percutaneous coronary intervention (PCI) or angioplasty.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15557

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Drug Eluting Stent Market?

The escalating prevalence of coronary heart disease is predicted to boost the expansion of the drug-eluting stent market. Coronary heart disease, characterized by the narrowing or blockage of coronary arteries due to plaque accumulation, can result in serious complications, including heart attacks and chest discomfort. Sedentary lifestyles, unhealthy food habits, aging demographics, and enhanced consciousness are contributing to the rise of this condition. Drug-eluting stents play a critical role in treating coronary heart disease, effectively unblocking or widening the constricted arteries, and dispensing medicine that prevents artery re-constriction, or restenosis. As an example, in May 2024, data from the Centers for Disease Control and Prevention, a US governmental entity, showed the prevalence of coronary heart disease among adults 18 and older had risen from 4.6% in 2020 to 4.9% in 2022. The growing prevalence of coronary heart disease is anticipated to further drive the expansion of the drug-eluting stent market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

#What Long-Term Growth Rate is Expected for theDrug Eluting Stent Market Between 2025 and 2034?

The market size for drug-eluting stents has experienced robust growth in the past few years. Its valuation is anticipated to rise from $7.63 billion in 2024 to about $8.29 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.6%. The growth during the historical period can be linked to several factors, including the requirement for enhanced treatment alternatives, clinical evidence supporting its use, approval from regulatory bodies, prevailing healthcare economics, and established guidelines and recommendations.

The market for drug eluting stents is projected to witness robust expansion in the coming years, escalating to $11.37 billion by 2029 with an 8.2% compound annual growth rate (CAGR). The surge expected in the forecast period is due to factors such as the increase in the aging population and chronic diseases burden, widening of indications, modifications in healthcare reimbursement policies, expansion of the global market, and focus on patient-centric care. Leading trends anticipated within this forecast period encompass personalized medical approaches, minimally invasive procedures, the emergence of innovative healthcare technologies, and cutting-edge drug formulations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15557

What New Market Trends Are Reshaping theDrug Eluting Stent Market and Its Opportunities?

Firms involved in the drug-eluting stent market are concentrating on the creation of novel delivery systems, including dual-layer balloons, to enhance patient results and push forward the intersessional cardiology sector. A dual-layer balloon in this type of system increases the accuracy of drug delivery and stent deployment by promoting superior control and evenly distributing the drug across the arterial wall. For instance, Medtronic Plc, a medical supply company based in Ireland, in August 2022, introduced Onyx Frontier, its newest generation of drug-eluting coronary stent systems. These new devices augment delivery mechanisms by utilizing the successful results and clinical data from the preceding version, Resolute Onyx DES. The Onyx Frontier DES relies on the same top-rated stent platform as its predecessor, offering a wide range of sizes to accommodate patients with diameters between 2.0mm and 5.0mm. Notable improvements of the Onyx Frontier DES include a revolutionary dual-layer balloon, a reduced crossing profile, and enhanced catheter flexibility. These enhancements result in a 16% boost in deliverability when compared to the previous generation, the Resolute Onyx DES, without compromising radial strength.

Who Are the Leading Market Players Fueling Growth in the Drug Eluting Stent Market Trend?

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

How is the Global Drug Eluting Stent Market Segemented?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinic

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Which Geographics are Influencing the Growth of the Drug Eluting Stent Market?

North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2025, By The Business Research Company:

Consumer Electronics Repair and Maintenance Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/consumer-electronics-repair-and-maintenance-global-market-report

Authorized Car Service Center Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/authorized-car-service-center-global-market-report

Maintenance Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/maintenance-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: